ICON Public (NASDAQ:ICLR) Releases FY24 Earnings Guidance

ICON Public (NASDAQ:ICLR) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share guidance of $13.90-14.10 for the period, compared to the consensus earnings per share estimate of $13.98. The company issued revenue guidance of $8.26-8.30 billion, compared to the consensus revenue estimate of $8.28 billion. ICON Public also updated its FY 2024 guidance to 13.900-14.100 EPS.

ICON Public Trading Down 0.1 %

ICLR opened at $217.99 on Tuesday. ICON Public has a 1-year low of $183.38 and a 1-year high of $347.72. The stock has a market capitalization of $17.98 billion, a PE ratio of 24.30, a PEG ratio of 1.54 and a beta of 1.20. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The firm has a 50-day moving average price of $211.31 and a two-hundred day moving average price of $270.81.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). The company had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the firm earned $3.10 EPS. As a group, equities analysts anticipate that ICON Public will post 13.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ICLR shares. Barclays dropped their price objective on ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. TD Cowen dropped their price target on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Leerink Partnrs raised shares of ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. Royal Bank of Canada started coverage on shares of ICON Public in a research report on Tuesday, January 7th. They set an “outperform” rating and a $263.00 target price for the company. Finally, StockNews.com lowered ICON Public from a “buy” rating to a “hold” rating in a research report on Thursday, September 19th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, ICON Public currently has an average rating of “Moderate Buy” and an average target price of $287.00.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.